Products with Anti-osteoporosis bioactivity
| Cat.No. | Product Name |
|---|---|
| BCN3639 | Toddaculine |
| 1. Toddaculine can not only inhibit the differentiation of osteoclasts via activation of the NF-κB, ERK 1/2, and p38 MAPK signaling pathways, but can induce differentiation and mineralization of osteoblasts by regulating differentiation factors. 2. Toddaculine may be beneficial for the prevention and treatment of osteoporosis. 3. Toddaculine displays a dual effect as a cell differentiating agent and apoptosis inducer in U-937 cells, suggesting it may serve as a pharmacological prototype for the development of novel anti-leukemic agents. | |
| BCN3869 | Alliin |
| 1. Alliin protects against Lipopolysaccharides (LPS)-induced acute lung injury (ALI) by activating PPARγ, which subsequently inhibits LPS-induced NF-κB activation and inflammatory response, alliin may be used as an anti-inflammatory agent in the treatment of ALI. 2. Alliin has antiglycating potential , it offers protection against glucose or methyglyoxal induced glycation of superoxide dismutase. 3. Alliin has a good antiglycating effect and hence is expected to have therapeutic potential in the prevention of glycation-mediated diabetic complications. 4. Alliin and sabinene have detectable levels of antimicrobial activity. 5. Alliin has an inhibitory effect in osteoclasteogenesis with a dose-dependent manner via blocking the c-Fos-NFATc1 signaling pathway, it could be a potential therapeutic agent in the treatment of osteoporosis. | |
| BCN4298 | Rubiadin 1-methyl ether |
| Rubiadin-1-methyl ether probed as Type I photosensitizers. Rubiadin 1-methyl ether decreases the number of parasites (schizonts) in a dose-dependent manner, and 100% of inhibition was obtained with 30 to 40 micrograms. Rubiadin-1-methyl ether shows strong enhancing activity for adipocyte differentiation, it could be beneficial in the treatment of diabetes. Rubiadin-1-methyl ether has therapeutic potential against osteoporosis, it can promote osteoblast proliferation and inhibit osteoclast TRAP activity and bone resorption, and the inhibitory effects on osteoclastic bone, antiosteoporotic activity of M. officinalis . | |
| BCN4557 | Furan-2-carboxylic acid |
| Furan-2-carboxylic acid, an orally active selective human cathepsin K inhibitor, may have the therapeutic potential for the treatment of diseases characterized by excessive bone loss including osteoporosis.Furan-2-carboxylic acid also has anti-bacterial effect, inhibits the proliferation of some slow-growing or difficult-to-culture bacteria on the plates. | |
| BCN4660 | Isotaxiresinol |
| 1. Isotaxiresinol may be useful for treatment of postmenopausal osteoporosis, especially for prevention of bone fracture induced by estrogen deficiency. 2. Isotaxiresinol prevents d-GalN/LPS-induced hepatic injury by inhibiting hepatocyte apoptosis through the blocking of TNF-alpha and IFN-gamma production by activated macrophages and direct inhibition of the apoptosis induced by TNF-alpha. | |
